ReviewDiseases (Basel, Switzerland)2024
Early- and Late-Onset Alzheimer's Disease: Two Sides of the Same Coin?
Review in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Distinct regional patterns of synaptic vulnerability across hippocampal and parahippocampal subregions in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Article
- Recent trends in anti-Alzheimer's potential of novel biologically active isatin analogues: synthetic strategies, structural activity relationship studies and molecular docking insights.Molecular diversity · 2026Review
- Diagnostic utility of Addenbrooke's Cognitive Examination III in differentiating Alzheimer's disease dementia, vascular dementia, and mixed dementia.Postepy psychiatrii neurologii · 2026Article
- MIR1255A regulates pathways critical for brain development, risk genes for depression and neurodevelopmental disorders.Translational psychiatry · 2026Article
- Neurosteroid-Mediated Neuroprotection via mTORC1/AMPK/BDNF Signaling Pathway in Alzheimer's Disease.Molecular neurobiology · 2026Review
- Article
- Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer's disease.Molecular diversity · 2026Review
- The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease.European radiology · 2026Review
- Decoding Alzheimer's Disease One Cell Class at a Time.Cellular and molecular neurobiology · 2026Review
- RBFOX1 association with age at onset of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Distinct Regulatory Genomic Architectures Distinguish Early-Onset from Late-Onset Alzheimer's Disease.Genes · 2026Article
- Microglial metabolic reprogramming drives the therapeutic effects of bavachinin on brain network function and memory in Alzheimer's disease.Frontiers in pharmacology · 2026Article
- Clinical and neuropsychological profile of Alzheimer's disease in Tunisia and the impact ofFrontiers in genetics · 2026Article
- Multimodal network alterations in diagnosis-age-defined early- and late-onset Alzheimer's disease.Frontiers in neuroscience · 2026Article
- Review
- Cross-cohort genetic risk prediction for Alzheimer's disease: a transfer learning approach using GWAS and deep learning models.BioData mining · 2025Article
- C16-siRNAs in Focus: Development of ALN-APP, a Promising RNAi-Based Therapeutic for Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Global burden, spatiotemporal disparities, and sex-specific trends of early- and late-onset Alzheimer's disease and other dementias: a comparative analysis and projections to 2035.BMC neurology · 2025Article
- The Endocannabinoid-Microbiota-Neuroimmune Super-System: A Unifying Feedback Architecture for Systems Resilience, Collapse Trajectories, and Precision Feedback Medicine.International journal of molecular sciences · 2025Review
- Preexisting Genetic Background Primes the Responses of Human Neurons to Amyloid β.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset Alzheimer's disease (EOAD), defined as Alzheimer's disease onset before 65 years of age, has been significantly less studied than the "classic" late-onset form (LOAD), although EOAD often presents with a more aggressive disease course, caused by variants in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.